Nektar Therapeutics (0UNL.L) LSE

36.76

+0.65(+1.80%)

Updated at January 14 03:03PM

Currency In USD

Valuation

Market Cap191.26M
Enterprise Value249.58M
P/E Ratio-4.27
PEG Ratio-0.47
Price/Sales Ratio11.89
Price/Book Ratio6.06
Enterprise/Revenue12.7
Enterprise/EBITDA-9.18

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin-1.93
Operating Margin-1.57

Management Effectiveness

Return On Assets-0.4
Return On Equity-3.57

Income Statement

Revenue98.43M
Revenue/Share4.44
Gross Profit67.74M
EBITDA-86.7M
Net Income-118.96M
Diluted EPS-8.68

Balance Sheet

Total Cash270.21M
Total Cash/Share19.18
Total Debt91.92M
Total Debt/Equity1.08
Current Ratio4.24
Book Value Per Share6.04

Price History

52-Week Change3,825.53
52-Week High38.7
52-Week Low35.77
Moving Average 50 Days52.6
Moving Average 200 Days41.75

Statistics

Average Volume7,660.14
Shares Outstanding20.34M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A